BioVie Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BIVI | ABVC | TOVX | CNSP | BLRX | NIKI | |
|---|---|---|---|---|---|---|
| Market cap | 11.63M | 26.69M | 8.72M | 6.34M | 9.26M | 5.27M |
| P/E (TTM) | — | — | 0.3 | — | — | — |
| Forward P/E | -2.4 | -2.3 | -1.0 | -11.1 | -0.7 | — |
| Price/book | 1.0 | 2.5 | 0.7 | 0.3 | 0.6 | 0.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −10.67% | −64.79% | −29.63% | −33.30% | −45.11% | −87.62% |
| Today | −22.54% | +1.51% | +4.40% | −4.62% | −2.62% | −3.98% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BIVI news ›BioVie to raise $4.74 million in registered direct offering
Proactive has a commercial relationship with BioVie Inc. This article was produced independently under Proactive's Editorial Standards Policy. BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Wednesday it will raise about $4.74 million in…
BioVie launches $4.74M direct offering and concurrent private placement
TradingView BioVie launches $4.74M direct offering and concurrent private placement - The company added that it entered into the deal with a single healthcare-focused institutional investor. - The company also launched a concur
Life Biosciences Announces First-in-Human Phase 1 Trial Data
Lifespan Research Institute Life Biosciences Announces First-in-Human Phase 1 Trial Data - Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial. Li
Novel drug bezisterim plans for further study in Long COVID. Here’s how the phase 2 trial came together.
Key points you should know: In September, BioVie reported phase 2 trial results for the novel drug bezisterim, which may improve Long COVID symptoms such as fatigue and post-exertional malaise (PEM) as well as neurological symptoms. This…
BioVersys announces first patient first visit in Phase 2b RIV-CARE trial of BV100
Professor David Paterson, Director of ADVANCE-ID, said: "Half of people with serious CRAB infections will die. Doctors desperately need new antibiotic options for treating these infections so we can lower the death rate. We hope that the…
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
Dr. Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID, will share results from the Company’s Phase 2 ADDRESS-LC trial evaluating bezisterim for the treatment of the ... BioVie Invited to Present Data on…
BioVie presents Phase 2 data on bezisterim in Long COVID
BioVie (BIVI) announced the presentation of results from the Phase 2 ADDRESS-LC study evaluating bezisterim in patients with Long COVID at the 1... BioVie presents Phase 2 data on bezisterim in Long COVID BioVie (BIVI) announced the…
More from 1 other outlet
BioVie presents results from SUNRISE-PD clinical trial evaluating bezisterim
BioVie (BIVI) announced the presentation of results from the Phase 2 SUNRISE-PD clinical trial evaluating bezisterim in early Parkinson’s patien... BioVie presents results from SUNRISE-PD clinical trial evaluating bezisterim BioVie (BIVI)…
Bezisterim shows promise in relieving long COVID symptoms
SAN DIEGO — Patients with severe symptoms of long COVID experienced relief with 12 weeks of Bezisterim therapy, according to a poster presented at the 151st Annual Meeting of the American Neurological Association. Bezisterim has the…
BioVie showcases Long COVID and Parkinson’s data at ANA2026, with findings in Annals of Neurology
Proactive has a commercial relationship with BioVie Inc. This article was produced independently under Proactive's Editorial Standards Policy. BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do joined Proactive's Stephen Gunnion after the…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com8
- proactiveinvestors.com5
- defenseworld.net1
- nasdaq.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.